Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG
2024

Fibrinogen as a Binding Partner for Lecanemab Biosimilar IgG

Sample size: 15 publication Evidence: moderate

Author Information

Author(s): J.‐P. Bellier, Román Viera Andrea M., Christiano Caitlyn, Anzai Juliana A. U., Moreno Stephanie, Campbell Emily C., Godwin Lucas, Li Amy, Chen Alan Y., Alam Sarah M., Saba Adriana, Yoo Han Bin, Yang Hyun‐Sik, Chhatwal Jasmeer P., Selkoe Dennis J., Liu Lei

Primary Institution: Department of Neurology, Brigham and Women's Hospital Harvard Medical School

Hypothesis

Does fibrinogen interact with lecanemab biosimilar IgG in human plasma?

Conclusion

Fibrinogen is identified as a significant plasma protein binding partner for lecanemab biosimilar IgG, which may affect its pharmacokinetics.

Supporting Evidence

  • Fibrinogen was identified as a likely binding partner for lecanemab biosimilar IgG.
  • Statistically significant disequilibrium ratios indicated binding of lecanemab to plasma components.
  • Binding affinity of lecanemab to fibrinogen was estimated at 318 mM, significantly lower than its affinity for Aβ.

Takeaway

This study found that a protein called fibrinogen can stick to a medicine used for Alzheimer's, which might change how well the medicine works in the body.

Methodology

The study used equilibrium dialysis, ELISA, and western blotting to assess the binding of lecanemab biosimilar to plasma proteins.

Limitations

The study does not rule out the possibility of other plasma proteins binding to lecanemab.

Participant Demographics

15 participants aged 45 and older, including individuals with Alzheimer's and Parkinson's disease.

Statistical Information

P-Value

0.0312

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1002/acn3.52227

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication